586 related articles for article (PubMed ID: 29309751)
21. Glucocorticoid receptor antagonist CORT113176 attenuates motor and neuropathological symptoms of Huntington's disease in R6/2 mice.
Gentenaar M; Meulmeester FL; van der Burg XR; Hoekstra AT; Hunt H; Kroon J; van Roon-Mom WMC; Meijer OC
Exp Neurol; 2024 Apr; 374():114675. PubMed ID: 38216109
[TBL] [Abstract][Full Text] [Related]
22. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
23. Ellagic acid rescues motor and cognitive deficits in the R6/2 mouse model of Huntington's disease by lowering mutant huntingtin protein.
Sun X; Zhu J; Sun XY; Ji M; Yu XL; Liu RT
Food Funct; 2020 Feb; 11(2):1334-1348. PubMed ID: 32043503
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.
Fisher SP; Black SW; Schwartz MD; Wilk AJ; Chen TM; Lincoln WU; Liu HW; Kilduff TS; Morairty SR
Brain; 2013 Jul; 136(Pt 7):2159-72. PubMed ID: 23801738
[TBL] [Abstract][Full Text] [Related]
25. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
26. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
27. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.
Cabezas-Llobet N; Vidal-Sancho L; Masana M; Fournier A; Alberch J; Vaudry D; Xifró X
Mol Neurobiol; 2018 Nov; 55(11):8263-8277. PubMed ID: 29526016
[TBL] [Abstract][Full Text] [Related]
28. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.
Liu SY; Yu XL; Zhu J; Liu XM; Zhang Y; Dong QX; Ma S; Liu RT
Brain Res; 2018 Oct; 1697():21-33. PubMed ID: 29902468
[TBL] [Abstract][Full Text] [Related]
29. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT.
Fang F; Peng T; Yang S; Wang W; Zhang Y; Li H
Int J Dev Neurosci; 2016 Aug; 52():66-74. PubMed ID: 27196502
[TBL] [Abstract][Full Text] [Related]
30. Laquinimod treatment in the R6/2 mouse model.
Ellrichmann G; Blusch A; Fatoba O; Brunner J; Reick C; Hayardeny L; Hayden M; Sehr D; Winklhofer KF; Saft C; Gold R
Sci Rep; 2017 Jul; 7(1):4947. PubMed ID: 28694434
[TBL] [Abstract][Full Text] [Related]
31. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
[TBL] [Abstract][Full Text] [Related]
32. Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease.
Meunier C; Merienne N; Jollé C; Déglon N; Pellerin L
Glia; 2016 Nov; 64(11):1841-56. PubMed ID: 27442486
[TBL] [Abstract][Full Text] [Related]
33. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
[TBL] [Abstract][Full Text] [Related]
34. Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease.
Yu-Taeger L; Stricker-Shaver J; Arnold K; Bambynek-Dziuk P; Novati A; Singer E; Lourhmati A; Fabian C; Magg J; Riess O; Schwab M; Stolzing A; Danielyan L; Nguyen HHP
Cells; 2019 Jun; 8(6):. PubMed ID: 31208073
[TBL] [Abstract][Full Text] [Related]
35. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.
Giralt A; Saavedra A; Carretón O; Arumí H; Tyebji S; Alberch J; Pérez-Navarro E
Hippocampus; 2013 Aug; 23(8):684-95. PubMed ID: 23576401
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
[TBL] [Abstract][Full Text] [Related]
37. Prevention of Huntington's Disease-Like Behavioral Deficits in R6/1 Mouse by Tolfenamic Acid Is Associated with Decreases in Mutant Huntingtin and Oxidative Stress.
Liu P; Li Y; Yang W; Liu D; Ji X; Chi T; Guo Z; Li L; Zou L
Oxid Med Cell Longev; 2019; 2019():4032428. PubMed ID: 31049134
[TBL] [Abstract][Full Text] [Related]
38. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
39. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
40. Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease.
Pietropaolo S; Bellocchio L; Ruiz-Calvo A; Cabanas M; Du Z; Guzmán M; Garret M; Cho YH
Neuropharmacology; 2015 Feb; 89():368-74. PubMed ID: 25123645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
